Literature DB >> 28733764

Cardiac sympathetic neuronal damage precedes myocardial fibrosis in patients with Anderson-Fabry disease.

Massimo Imbriaco1, Teresa Pellegrino2, Valentina Piscopo1, Mario Petretta3, Andrea Ponsiglione1, Carmela Nappi1, Marta Puglia1, Serena Dell'Aversana1, Eleonora Riccio4, Letizia Spinelli1, Antonio Pisani4, Alberto Cuocolo5.   

Abstract

PURPOSE: Cardiac sympathetic denervation may be detectable in patients with Anderson-Fabry disease (AFD), suggesting its usefulness for early detection of the disease. However, the relationship between sympathetic neuronal damage measured by 123I-metaiodobenzylguanidine (MIBG) imaging with myocardial fibrosis on cardiac magnetic resonance (CMR) is still unclear.
METHODS: Cardiac sympathetic innervation was assessed by 123I-MIBG single-photon emission computed tomography (SPECT) in 25 patients with genetically proved AFD. Within one month from MIBG imaging, all patients underwent contrast-enhanced CMR. MIBG defect size and fibrosis size on CMR were measured for the left ventricle (LV) and expressed as %LV.
RESULTS: Patients were divided into three groups according to MIBG and CMR findings: (1) matched normal, without MIBG defects and without fibrosis on CMR (n = 10); (2) unmatched, with MIBG defect but without fibrosis (n = 5); and (3) matched abnormal, with MIBG defect and fibrosis (n = 10). The three groups did not differ with respect to age, gender, α-galactosidase, proteinuria, glomerular filtration rate, and troponin I, while New York Heart Association class (p = 0.008), LV hypertrophy (p = 0.05), and enzyme replacement therapy (p = 0.02) were different among groups. Although in patients with matched abnormal findings, there was a significant correlation between MIBG defect size and area of fibrosis at CMR (r2 = 0.98, p < 0.001), MIBG defect size was larger than fibrosis size (26 ± 23 vs. 18 ± 13%LV, p = 0.02).
CONCLUSION: Sympathetic neuronal damage is frequent in AFD patients, and it may precede myocardial damage, such as fibrosis. Thus, 123I-MIBG imaging can be considered a challenging technique for early detection of cardiac involvement in AFD.

Entities:  

Keywords:  Cardiac magnetic resonance imaging; Fabry disease; Fibrosis; Radionuclide imaging; Sympathetic nervous system

Mesh:

Substances:

Year:  2017        PMID: 28733764     DOI: 10.1007/s00259-017-3778-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  38 in total

Review 1.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.

Authors:  Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Warren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani
Journal:  Circulation       Date:  2002-01-29       Impact factor: 29.690

2.  Observer reproducibility of results from a low-dose 123I-metaiodobenzylguanidine cardiac imaging protocol in patients with heart failure.

Authors:  Teresa Pellegrino; Mario Petretta; Serena De Luca; Stefania Paolillo; Antonio Boemio; Raffaella Carotenuto; Maria Piera Petretta; Carmine di Nuzzo; Pasquale Perrone-Filardi; Alberto Cuocolo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-06-06       Impact factor: 9.236

3.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

4.  Focal Reduction in Cardiac 123I-Metaiodobenzylguanidine Uptake in Patients With Anderson-Fabry Disease.

Authors:  Saori Yamamoto; Hideaki Suzuki; Koichiro Sugimura; Shunsuke Tatebe; Tatsuo Aoki; Masanobu Miura; Nobuhiro Yaoita; Haruka Sato; Katuya Kozu; Hideki Ota; Kentaro Takanami; Kei Takase; Hiroaki Shimokawa
Journal:  Circ J       Date:  2016-10-25       Impact factor: 2.993

5.  Quantitative analysis of 123I-meta-iodobenzylguanidine (MIBG) uptake in hypertrophic cardiomyopathy.

Authors:  K Nakajima; H Bunko; J Taki; M Shimizu; A Muramori; K Hisada
Journal:  Am Heart J       Date:  1990-06       Impact factor: 4.749

6.  Myocardial imaging with a radioiodinated norepinephrine storage analog.

Authors:  D M Wieland; L E Brown; W L Rogers; K C Worthington; J L Wu; N H Clinthorne; C A Otto; D P Swanson; W H Beierwaltes
Journal:  J Nucl Med       Date:  1981-01       Impact factor: 10.057

7.  Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease.

Authors:  Johannes Krämer; Markus Niemann; Dan Liu; Kai Hu; Wolfram Machann; Meinrad Beer; Christoph Wanner; Georg Ertl; Frank Weidemann
Journal:  Eur Heart J       Date:  2013-03-21       Impact factor: 29.983

8.  Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy.

Authors:  E B Henderson; J K Kahn; J R Corbett; D E Jansen; J J Pippin; P Kulkarni; V Ugolini; M S Akers; C Hansen; L M Buja
Journal:  Circulation       Date:  1988-11       Impact factor: 29.690

9.  Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium.

Authors:  James C C Moon; Bhavesh Sachdev; Andrew G Elkington; William J McKenna; Atul Mehta; Dudley J Pennell; Philip J Leed; Perry M Elliott
Journal:  Eur Heart J       Date:  2003-12       Impact factor: 29.983

Review 10.  Fibrosis: a key feature of Fabry disease with potential therapeutic implications.

Authors:  Frank Weidemann; Maria D Sanchez-Niño; Juan Politei; João-Paulo Oliveira; Christoph Wanner; David G Warnock; Alberto Ortiz
Journal:  Orphanet J Rare Dis       Date:  2013-08-06       Impact factor: 4.123

View more
  10 in total

1.  Cardiac amyloidosis: A new challenge of multimodality imaging.

Authors:  Carmela Nappi; Roberta Assante; Emilia Zampella; Alberto Cuocolo
Journal:  J Nucl Cardiol       Date:  2018-06-26       Impact factor: 5.952

2.  Left Ventricular Mass in Hypertrophic Cardiomyopathy Assessed by 2D-Echocardiography: Validation with Magnetic Resonance Imaging.

Authors:  Maria Angela Losi; Massimo Imbriaco; Grazia Canciello; Filomena Pacelli; Carlo Di Nardo; Raffaella Lombardi; Raffaele Izzo; Costantino Mancusi; Andrea Ponsiglione; Serena Dell'Aversana; Alberto Cuocolo; Giovanni de Simone; Bruno Trimarco; Emanuele Barbato
Journal:  J Cardiovasc Transl Res       Date:  2019-09-05       Impact factor: 4.132

Review 3.  Fabry Disease and the Heart: A Comprehensive Review.

Authors:  Olga Azevedo; Filipa Cordeiro; Miguel Fernandes Gago; Gabriel Miltenberger-Miltenyi; Catarina Ferreira; Nuno Sousa; Damião Cunha
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

Review 4.  Myocardial ischaemia reperfusion injury and cardioprotection in the presence of sensory neuropathy: Therapeutic options.

Authors:  Péter Bencsik; Kamilla Gömöri; Tamara Szabados; Péter Sántha; Zsuzsanna Helyes; Gábor Jancsó; Péter Ferdinandy; Anikó Görbe
Journal:  Br J Pharmacol       Date:  2020-03-21       Impact factor: 8.739

5.  Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD modified Delphi consensus initiative.

Authors:  Derralynn A Hughes; Patricio Aguiar; Patrick B Deegan; Fatih Ezgu; Andrea Frustaci; Olivier Lidove; Aleš Linhart; Jean-Claude Lubanda; James C Moon; Kathleen Nicholls; Dau-Ming Niu; Albina Nowak; Uma Ramaswami; Ricardo Reisin; Paula Rozenfeld; Raphael Schiffmann; Einar Svarstad; Mark Thomas; Roser Torra; Bojan Vujkovac; David G Warnock; Michael L West; Jack Johnson; Mark J Rolfe; Sandro Feriozzi
Journal:  BMJ Open       Date:  2020-10-10       Impact factor: 2.692

Review 6.  Multimodality Imaging in Cardiomyopathies with Hypertrophic Phenotypes.

Authors:  Emanuele Monda; Giuseppe Palmiero; Michele Lioncino; Marta Rubino; Annapaola Cirillo; Adelaide Fusco; Martina Caiazza; Federica Verrillo; Gaetano Diana; Alfredo Mauriello; Michele Iavarone; Maria Angela Losi; Maria Luisa De Rimini; Santo Dellegrottaglie; Antonello D'Andrea; Eduardo Bossone; Giuseppe Pacileo; Giuseppe Limongelli
Journal:  J Clin Med       Date:  2022-02-07       Impact factor: 4.964

Review 7.  Multimodality Cardiac Imaging in Cardiomyopathies: From Diagnosis to Prognosis.

Authors:  Guillem Casas; José F Rodríguez-Palomares
Journal:  J Clin Med       Date:  2022-01-24       Impact factor: 4.241

Review 8.  Cardiac Imaging in Anderson-Fabry Disease: Past, Present and Future.

Authors:  Roberta Esposito; Ciro Santoro; Giulia Elena Mandoli; Vittoria Cuomo; Regina Sorrentino; Lucia La Mura; Maria Concetta Pastore; Francesco Bandera; Flavio D'Ascenzi; Alessandro Malagoli; Giovanni Benfari; Antonello D'Andrea; Matteo Cameli
Journal:  J Clin Med       Date:  2021-05-06       Impact factor: 4.241

Review 9.  Multimodality imaging approach to Fabry cardiomyopathy: Any role for nuclear cardiology?

Authors:  Wanda Acampa; Adriana D'Antonio; Massimo Imbriaco; Antonio Pisani; Alberto Cuocolo
Journal:  J Nucl Cardiol       Date:  2020-05-06       Impact factor: 3.872

Review 10.  SPECT vs. PET in cardiac innervation imaging: clash of the titans.

Authors:  Rudolf A Werner; Xinyu Chen; Mitsuru Hirano; Steven P Rowe; Constantin Lapa; Mehrbod S Javadi; Takahiro Higuchi
Journal:  Clin Transl Imaging       Date:  2018-07-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.